Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"
Executive Summary
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?